Study: NCT01373450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxyntomodulin
Description: IV infusion in the morning of the day of GGI (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxyntomodulin
Description: IV infusion in the morning of the day of GGI (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxyntomodulin
Description: IV infusion in the morning of the day of GGI (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxyntomodulin
Description: IV infusion in the morning of the day of GGI (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxyntomodulin
Description: IV infusion in the morning of the day of GGI (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxyntomodulin
Description: IV infusion in the morning of the day of GGI (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Liraglutide
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Liraglutide
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Liraglutide
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Liraglutide
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Liraglutide
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)